secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001753926-25-001964
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos Therapeutics appoints Andrew Einhorn to Board of Directors; board expands to eight
--------------------------------------------------------------------------------

- Andrew Einhorn appointed to Board effective December 23, 2025, filling newly created eighth seat.
- Einhorn will serve on Audit and Compensation Committees; term until 2026 annual meeting.
- Einhorn brings 40+ years of finance, capital markets, and life sciences experience.
- Granted 12,000 RSUs vesting January 1, 2027, plus standard non-employee director compensation.
- Board expanded from seven to eight members; Einhorn deemed independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001964/0001753926-25-001964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001964/g085052_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer